MEDI:GATE NEWS Held a regular shareholders’ meeting of Huzel, aims to double the overseas market this year

On the 26th, Huzel held the 20th regular shareholders’ meeting at the Chuncheon Bio Industry Promotion Agency in Chuncheon-si, Gangwon-do, where the company’s headquarters are located.

At this shareholders’ meeting, Huzel decided on a total of five agendas according to the original proposal, including approval of the financial statements for the 20th term (2020.01.

In 2020, Huzel’s sales reached about 21 billion won based on consolidated financial statements, breaking a record-breaking record. Operating profit was 78.1 billion won and net income was about 44.5 billion won.

Through a greeting, Huzel CEO Ji-Hoon Son introduced the status of Chinese businesses and big market advances, and revealed plans and aspirations to double global sales this year compared to the previous year.

“Last year, the first Korean company to enter the Chinese botulinum toxin market, successfully held a launching event for’Letybo’ and started full-fledged local sales,” said Son. “We aim to achieve 10% market share this year. “He said.

“As the No. 1 company in Korea for 5 consecutive years, we plan to strengthen our competitiveness by actively utilizing the nationwide distribution network of Chinese hospitals and clinics built by our partner company, Sahwan Pharmaceutical, in addition to Huzel’s excellent marketing capabilities. Through this, we will carry out various activities such as operating an academic training center for local doctors and related people.”

While continuing its unstoppable growth with full-fledged business development in China, Huzel expects to obtain an item license in the European market for botulinum toxin formulations this year. Is the plan.

“We plan to establish and develop marketing strategies to expand market and share in overseas markets that have already entered the market such as Brazil, Thailand, and Taiwan,” said Sohn. If you do, global sales will increase significantly this year,” he predicted.

.Source